Timothy P. Clackson
Tim Clackson is President of Research and Development and Chief Scientific Officer at ARIAD Pharmaceuticals Inc., an integrated oncology company headquartered in Cambridge, Massachusetts and Lausanne, Switzerland. During his 20 year career at ARIAD, Dr. Clackson has held a series of increasingly senior positions, including CSO since 2003 and President of R&D since 2010. Dr. Clackson has overall operational and strategic responsibility for R&D at ARIAD, including drug discovery, preclinical and translational research, clinical development, and manufacturing and technical operations. He led the multi-disciplinary R&D team that discovered and developed Iclusig (ponatinib), a pan-BCR-ABL inhibitor approved in the US and Europe for the treatment of resistant CML and Ph+ALL; and investigational agents brigatinib, an ALK inhibitor; ridaforolimus, an mTOR inhibitor licensed to Medinol Ltd.; and AP1903, a small molecule regulator for cancer cell therapy licensed to Bellicum Pharmaceuticals. From 1991 to 1994, Dr. Clackson was a postdoctoral fellow at Genentech Inc., where his studies on growth hormone receptor defined the now-established “hot spot” paradigm for how proteins interact. Dr. Clackson received his Ph.D. in Biology from Cambridge University in 1991, for research conducted under Dr Greg Winter, FRS at the MRC Laboratory of Molecular Biology into antibody engineering and the development of antibody phage display technology, subsequently commercialized by Cambridge Antibody Technology. He received his B.A. degree in Biochemistry from Oxford University in 1987.